These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 26965579)
1. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. Cowan M; Springer S; Nguyen D; Taheri D; Guner G; Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Cunha I; Fujita K; Ertoy D; Bivalacqua TJ; Kinzler K; Vogelstein B; Netto GJ; Papadopoulos N Mod Pathol; 2016 May; 29(5):511-5. PubMed ID: 26965579 [TBL] [Abstract][Full Text] [Related]
2. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Cowan ML; Springer S; Nguyen D; Taheri D; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; Del Carmen Rodriguez Pena M; VandenBussche CJ; Olson MT; Cunha I; Fujita K; Ertoy D; Kinzler K; Bivalacqua T; Papadopoulos N; Vogelstein B; Netto GJ Hum Pathol; 2016 Jul; 53():8-13. PubMed ID: 26980028 [TBL] [Abstract][Full Text] [Related]
3. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872 [TBL] [Abstract][Full Text] [Related]
4. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899 [TBL] [Abstract][Full Text] [Related]
5. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications. Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765 [TBL] [Abstract][Full Text] [Related]
7. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications. Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924 [TBL] [Abstract][Full Text] [Related]
8. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. Zheng X; Zhuge J; Bezerra SM; Faraj SF; Munari E; Fallon JT; Yang XJ; Argani P; Netto GJ; Zhong M J Hematol Oncol; 2014 Jul; 7():47. PubMed ID: 25042800 [TBL] [Abstract][Full Text] [Related]
9. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer. Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227 [TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487 [TBL] [Abstract][Full Text] [Related]
12. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. Cheng L; Zhang S; Wang M; Lopez-Beltran A Hum Pathol; 2023 Mar; 133():56-75. PubMed ID: 35700749 [TBL] [Abstract][Full Text] [Related]
13. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021 [TBL] [Abstract][Full Text] [Related]
14. Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Rodriguez Pena MDC; Tregnago AC; Eich ML; Springer S; Wang Y; Taheri D; Ertoy D; Fujita K; Bezerra SM; Cunha IW; Raspollini MR; Yu L; Bivalacqua TJ; Papadopoulos N; Kinzler KW; Vogelstein B; Netto GJ Virchows Arch; 2017 Dec; 471(6):761-767. PubMed ID: 28597078 [TBL] [Abstract][Full Text] [Related]
16. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299 [TBL] [Abstract][Full Text] [Related]
17. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309 [TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations in penile squamous cell carcinoma: high frequency in non-HPV-related type and association with favorable clinicopathologic features. Kim SK; Kim JH; Han JH; Cho NH; Kim SJ; Kim SI; Choo SH; Kim JS; Park B; Kwon JE J Cancer Res Clin Oncol; 2021 Apr; 147(4):1125-1135. PubMed ID: 33635430 [TBL] [Abstract][Full Text] [Related]
19. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. Roggisch J; Ecke T; Koch S Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529 [TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]